Relation between FMS-like tyrosine kinase 3 factor and hematological parameter in acute lymphoblastic leukemia patients by flow cytometry

被引:0
|
作者
Al-Ali, Zainab [1 ]
Mohammed, Bassam [2 ]
机构
[1] Basra Children Teaching Specialty Hosp, Dept Pathol, Basra, Iraq
[2] Al Nahrain Univ, Coll Med, Dept Pathol, Baghdad, Iraq
关键词
Childhood acute lymphoblastic leukemia; FMS-like tyrosine kinase 3; receptor tyrosine kinase; ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; PROGNOSTIC-SIGNIFICANCE; ACTIVATING MUTATION; CD135; EXPRESSION; FLT3; MUTATIONS; CHILDREN; DOMAIN; LOOP; AGE;
D O I
10.4103/ijh.ijh_49_22
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Acute lymphoblastic leukemia (ALL) is a heterogeneous disorder that is caused by the clonal expansion of immature lymphoid cells with a high rate among children more than adults. FMS-like tyrosine kinase 3 (FLT3) is a cellular receptor belongs to the Class III receptor tyrosine kinase family. The main expression of FLT3 on bone marrow (BM) cells especially CD34+ hematopoietic stem cells, early progenitor cells, dendritic progenitor cells, and other cells of organs (brain, placenta, and testis). Activation of FLT3 results in increased cell proliferation, decreased cell apoptosis, and inhibition of differentiation of cells. This study aims to detect the expression of the FLT3 cluster of differentiation antigen 135 (CD135) in childhood B-ALL patients. Moreover, to correlate this expression with hematological parameters include a complete blood count and BM examination findings and clinical parameters. PATIENTS, MATERIALS AND METHODS: This study was conducted on 30 newly diagnosed pediatric ALL patients. Diagnosis of the disease was based on the blood film, BM examination findings, cytochemistry, and flowcytometry of peripheral blood (PB) and/or BM sample, 1 ml of PB and/or BM sample was collected in EDTA tubes for flowcytometry for detection of CD135. RESULTS: This study found that male patients were more than females with a male-to-female ratio (1.14:1) and a median age of 5 years. Most of the patients had a positive expression of the FLT3 receptor and according to NCI risk groups, 60% of patients fall in the standard risk and 40% in the high-risk group. There was a significant correlation between the level of FLT3 (CD135) and age but no significant correlation with hemoglobin, white blood count, platelets, and peripheral or BM blast percentage. CONCLUSION: In this study, the patients with positive FLT3 blast cells (which is a bad prognostic factor) were associated with good prognostic factors. This proves that FLT3 is an independent prognostic factor.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 50 条
  • [1] Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia
    Prescott, Hillary
    Kantarjian, Hagop
    Cortes, Jorge
    Ravandi, Farhad
    EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (03) : 407 - 423
  • [2] Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
    Swords, R.
    Freeman, C.
    Giles, F.
    LEUKEMIA, 2012, 26 (10) : 2176 - 2185
  • [3] Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
    R Swords
    C Freeman
    F Giles
    Leukemia, 2012, 26 : 2176 - 2185
  • [4] FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia
    Parcells, Bertrand W.
    Ikeda, Alan K.
    Simms-Waldrip, Tiffany
    Moore, Theodore B.
    Sakamoto, Kathleen M.
    STEM CELLS, 2006, 24 (05) : 1174 - 1184
  • [5] Fms-like tyrosine kinase 3 positive acute myeloid leukemia
    Isidori, Alessandro
    Visani, Giuseppe
    Ferrara, Felicetto
    CURRENT OPINION IN ONCOLOGY, 2023, 35 (06) : 589 - 593
  • [6] Molecular Involvement and Prognostic Importance of Fms-like Tyrosine Kinase 3 in Acute Myeloid Leukemia
    Shahab, Sadaf
    Shamsi, Tahir S.
    Ahmed, Nuzhat
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (09) : 4215 - 4220
  • [7] FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
    Novatcheva, Elli D.
    Anouty, Yasmine
    Saunders, Ila
    Mangan, James K.
    Goodman, Aaron M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03) : E161 - E184
  • [8] FMS-like tyrosine kinase 3 inhibitors: a patent review
    Lee, Jongkook
    Paek, Seung-Mann
    Han, Sun-Young
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (04) : 483 - 503
  • [9] Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
    Pemmaraju, Naveen
    Kantarjian, Hagop
    Andreeff, Michael
    Cortes, Jorge
    Ravandi, Farhad
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (07) : 943 - 954
  • [10] Fms-Like Tyrosine Kinase 3 Mutations in Childhood Acute Leukemias and their Association with Prognosis
    Karabacak, Bircan Hizli
    Erbey, Fatih
    Bayram, Ibrahim
    Yilmaz, Sema
    Acipayam, Can
    Kilinc, Yurdanur
    Tanyeli, Atila
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2010, 11 (04) : 923 - 927